This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Goldman Sachs, Morgan: Premarket Trading

(Premarket story updated with Goldman Sachs and Morgan Stanley news, as well as share price information.)
NEW YORK ( TheStreet) -- Yesterday Calyon Securities analyst Mike Mayo lowered his estimates for Goldman Sachs (GS - Get Report) and Morgan Stanley (MS - Get Report) on worries about the weakness in rates products. Mayo lowered his fourth-quarter earnings estimate for Morgan Stanley to 40 cents per share from 61 cents, while decreasing his expectation for Goldman to $3.75 per share from $4.20.

Morgan Stanley is down 0.07%, or 2 cents, to $27.26, while Goldman Sachs is dropping 0.08%, or 13 cents, to $167.50 in premarket trading.

Qiao Xing Universal Resources (XING) announced yesterday that it posted pictures of a newly acquired mine online and that it plans to launch a new Web site in early January.

"We are making continuous efforts to enhance our transparency and improve communications with investors to convey the exciting developments within our company," Qiao Xing chairman and CEO Ruilin Wu said. "As part of these efforts, we are also considering an on-site visit in the spring of 2011 in Chifeng, where most of our mining businesses are located."

Shares of the company are climbing 9.59%, or 26 cents, to $2.97 in premarket trading.

JPMorgan Chase (JPM - Get Report) and Barclays (BARC) said they will not oppose MBIA's (MBI - Get Report) plan to split its municipal bond insurance business from its structured finance operations. U.S. bond insurer MBIA is receiving opposition from over a dozen major banks including Citigroup (C - Get Report) and Morgan Stanley.

MBIA shares are down 0.01%, or 1 cents, to $10.35 in premarket trading.

Endo Pharmaceuticals (ENDP - Get Report) received regulatory approval from the Food and Drug Administration for its Fortesta gel product for the treatment of men with low testosterone. Endo expects to launch the product in the U.S. in early 2011.

Shares of the company are up 6.47%, or $2.28, to $37.50 in premarket trading.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AKRX $23.82 -2.30%
C $44.31 -0.78%
ENDP $25.91 -5.30%
GS $159.21 -0.54%
IPXL $32.28 0.03%


Chart of I:DJI
DOW 17,638.46 -12.80 -0.07%
S&P 500 2,048.99 -2.13 -0.10%
NASDAQ 4,719.1260 -6.5130 -0.14%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs